2 news items
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
AKRO
ETNB
LLY
5 Jun 24
endpoint.
Larger and longer trials are needed to assess the efficacy and safety of tirzepatide for non-cirrhotic MASH
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AKRO
10 May 24
, including up to 100 patients rolled over from Phase 2b studies of EFX. The primary endpoint of safety and tolerability will be assessed after 52 weeks
- Prev
- 1
- Next